Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Operating Expenses for 6 consecutive years, with $127.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 36.54% to $127.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $269.4 million through Dec 2025, down 24.91% year-over-year, with the annual reading at $269.4 million for FY2025, 24.91% down from the prior year.
  • Operating Expenses hit $127.6 million in Q4 2025 for Lyell Immunopharma, up from $37.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $201.2 million in Q4 2024 to a low of $37.3 million in Q3 2025.
  • Historically, Operating Expenses has averaged $68.6 million across 5 years, with a median of $59.3 million in 2023.
  • Biggest five-year swings in Operating Expenses: tumbled 38.18% in 2021 and later soared 237.96% in 2024.
  • Year by year, Operating Expenses stood at $50.4 million in 2021, then rose by 25.44% to $63.2 million in 2022, then decreased by 5.78% to $59.5 million in 2023, then skyrocketed by 237.96% to $201.2 million in 2024, then crashed by 36.54% to $127.6 million in 2025.
  • Business Quant data shows Operating Expenses for LYEL at $127.6 million in Q4 2025, $37.3 million in Q3 2025, and $47.1 million in Q2 2025.